Pertschuk L P, Macchia R J, Feldman J G, Brady K A, Levine M, Kim D S, Eisenberg K B, Rainford E, Prins G S, Greene G L
Department of Pathology, State University of New York, Brooklyn.
Ann Surg Oncol. 1994 Nov;1(6):495-503. doi: 10.1007/BF02303615.
Numerous problems are associated with biochemical androgen receptor (AR) assay performance and interpretation in prostatic cancer. The purpose of this study was to determine if a novel immunocytochemical AR assay performed on intact tissue sections would prove useful in prognosticating endocrine response and survival.
A prospective study was done on 63 prostatic carcinomas maintained in liquid nitrogen for over a decade. The study used the peroxidase-antiperoxidase system and a polyclonal anti-AR antibody.
Marked tissue and cellular heterogeneity of nuclear AR was apparent. A cut-off of 10% AR-positive cells maximized assay prognostic efficiency. Frequency of positivity was 48% and correlated significantly with endocrine response (p = 0.03), time to progression (p = 0.0016), and survival (p = 0.02), but not with grade, stage, or ethnicity.
This AR assay could be prognostically useful in the clinical management of prostate cancer and is suitable for use in the community hospital laboratory.
前列腺癌中生化雄激素受体（AR）检测的性能及解读存在诸多问题。本研究的目的是确定在完整组织切片上进行的新型免疫细胞化学AR检测是否有助于预测内分泌反应和生存情况。
对63例保存在液氮中超过十年的前列腺癌进行了一项前瞻性研究。该研究使用了过氧化物酶-抗过氧化物酶系统和一种多克隆抗AR抗体。
核AR存在明显的组织和细胞异质性。以10% AR阳性细胞为临界值可使检测的预后效率最大化。阳性频率为48%，与内分泌反应（p = 0.03）、进展时间（p = 0.0016）和生存情况（p = 0.02）显著相关，但与分级、分期或种族无关。
这种AR检测在前列腺癌的临床管理中可能具有预后价值，且适用于社区医院实验室。
